Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.-论文-万方医学网

作者： Gordon R,Bernard ^[1] ; Bruno,Francois ; Jean-Paul,Mira ; Jean-Louis,Vincent ; R Phillip,Dellinger ; James A,Russell ; Steven P,Larosa ; Pierre-Francois,Laterre ; Mitchell M,Levy ; Wayne,Dankner ; Nicola,Schmitt ; Justin,Lindemann ; Xavier,Wittebole

作者单位： 1Division of Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN. 2Service de Réanimation Polyvalente, CIC-P 0801, CHU Dupuytren, Limoges, Cedex, France. 3Hôpitaux Paris Centre, AP-HP; Université Paris Descartes, Faculté de médecine, Paris, France and Cochin Institute, INSERM U567, CNRS UMR 8104, Paris, France. 4Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 5Department of Medicine, Cooper University Hospital, Camden, NJ. 6Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada. 7Division of Infectious Diseases, Beverly Hospital, Beverly, MA. 8Critical Care Department, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 9Department of Medicine, Brown University, Providence, RI. 10Worldwide Medical Services Department, PAREXEL International, Durham, NC. 11AstraZeneca, Alderley Park, Macclesfield, United Kingdom. ^[1]

主题词成年人(Adult);老年人(Aged);置信区间(Confidence Intervals);剂量效应关系, 药物(Dose-Response Relationship, Drug);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);评价研究(主题)(Evaluation Studies as Topic);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);免疫球蛋白Fab片段(Immunoglobulin Fab Fragments);输注, 静脉内(Infusions, Intravenous);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);中年人(Middle Aged);危险性评估(Risk Assessment);脓毒症(Sepsis);休克, 脓毒性(Shock, Septic);统计学, 非参数(Statistics, Nonparametric);存活率(Survival Rate);治疗结果(Treatment Outcome);肿瘤坏死因子α(Tumor Necrosis Factor-alpha)

DOI 10.1097/CCM.0000000000000043

PMID 24335445

发布时间 2022-03-11

检索历史清除

Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.

Critical care medicine

相似文献

Critical care medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.

Critical care medicine

相似文献

Critical care medicine

相关期刊

检索历史清除